Companion Diagnostics Archives

Companion Diagnostics Play a Confusing Role with PD-1 Inhibitors

May 31, 2016 | News

There are now three approved drugs that target PD-1 either directly or indirectly, and more are under development.While these drugs all seek to inhibit PD-1’s immune suppressive activity, they are quite different in the ways that companion diagnostic tests play...

Amplion, BIO, and BioMedTracker release new report on ground breaking role biomarkers have in increasing Likelihood of Approval (LOA)

May 25, 2016 | Biomarkers, News

New Report from Amplion, BIO, and BioMedTracker examined ~10,000 clinical trials to make groundbreaking conclusion regarding biomarkers. Bend, Ore., May 25, 2016., May 25, 2016 – Amplion (developers of BiomarkerBaseTM), Biomedtracker, and BIO announces the...

New Releases Do Little to Clarify FDA’s Definition of Complementary Diagnostics

May 25, 2016 | News

Some time back, FDA alluded to a new category of biomarker termed “complementary diagnostic.” This was the Agency’s first use of a categorization beyond “companion diagnostic.” Since then there have been several public announcements of...

Biomarkers Triple Clinical Trial Success Rate According To Largest Study Of Its Kind

May 25, 2016 | Biomarkers, News

New Report from Amplion, BIO, and BioMedTracker examined ~10,000 clinical trials to make groundbreaking conclusion regarding biomarkers. 09:25 ET from Amplion BEND, Ore., May 25, 2016 /PRNewswire/ — Amplion (inventors of BiomarkerBase™), Biomedtracker,...

PR NewsWire: A New Report From Amplion: Companion Diagnostic Biomarker Trends.

May 4, 2016 | News

Trends in biomarker types and uses, test development, and drug enablement are described in this new report, along with a breakdown of the companies that are doing the most to advance precision medicine. 10:00 ET from Amplion Inc. BEND, Ore., May 4, 2016 /PRNewswire/...

« Older Entries